Canberra Advocates Push to Reform Medicinal Cannabis Driving Laws

Current ACT law treats all THC presence as per se impairment, barring no exception for medicinal users.

Under Section 20 of the Road Transport (Drug Driving) Act 2007, any driver in the Australian Capital Territory found with detectable delta-9-tetrahydrocannabinol in oral fluid or blood commits a strict-liability offense. The statute makes no distinction between recreational use and medicinal prescription. Prescribed patients who consume cannabis oil or flower days before driving face automatic license suspension and criminal penalties if stopped at a roadside drug test, even when demonstrably unimpaired.

The ACT's approach mirrors zero-tolerance frameworks in New South Wales, Victoria, and Queensland. Tasmania and South Australia maintain similar per se standards. No Australian jurisdiction currently provides a statutory defense for medicinal cannabis prescription holders, though Tasmania's Road Safety (Alcohol and Drugs) Act 1970 has been the subject of reform proposals since 2024.

THC metabolites remain detectable in saliva for 12 to 24 hours after inhalation and up to 72 hours in chronic users, according to pharmacokinetic studies published in Clinical Chemistry. Patients using daily oral tinctures or capsules for chronic pain, epilepsy, or chemotherapy-related nausea report testing positive days after last dose. Psychoactive effects? Long gone.

Reform advocates cite the disconnect between federal medicinal access and state-level criminal liability.

The Therapeutic Goods Administration approved medicinal cannabis under the Special Access Scheme and Authorised Prescriber pathways in 2016, establishing a federal framework for lawful prescription. As of June 2026, more than 400,000 Australians hold active medicinal cannabis prescriptions, according to TGA data. Canberra-based patient advocacy groups argue that ACT driving laws criminalize conduct the Commonwealth explicitly permits.

On a strict reading of the Road Transport Act, a patient who consumes a TGA-approved cannabis product in full compliance with their prescription commits an offense the moment they operate a vehicle with residual THC, regardless of dosage timing or impairment. The statute doesn't require proof of recent use, only presence. Lawful medicine, unlawful driving.

The current framework punishes patients for following their doctor's orders, treating medicinal THC as contraband despite federal approval.

Advocates point to the ACT's decriminalization of adult-use cannabis possession in 2020 as evidence of evolving policy. The Personal Cannabis Use Amendment Act 2019 permits possession of up to 50 grams and cultivation of two plants per person, yet driving laws remain unchanged. Recreational users and medicinal patients face identical penalties at roadside checkpoints.

Proposed reforms would establish impairment thresholds or statutory defenses for prescription holders.

Two reform models have circulated in Canberra policy discussions. The first would amend Section 20 to create a statutory defense for drivers holding valid TGA prescriptions who can demonstrate compliance with dosing instructions and absence of recent use within a defined window, such as eight hours. This mirrors defenses available for prescribed opioids and benzodiazepines under existing ACT traffic law.

A second model would replace the zero-tolerance standard with a blood-concentration threshold, similar to alcohol's 0.05 percent BAC limit. Proponents cite emerging research on THC blood levels and impairment correlation, though no Australian jurisdiction has adopted a per se THC limit tied to impairment science. Colorado's five-nanogram-per-milliliter whole-blood standard is frequently referenced, though its evidentiary basis remains contested in U.S. courts.

Neither model has advanced to formal legislative drafting in the ACT Legislative Assembly. The territory's Road Safety Minister hasn't publicly endorsed specific reform language, though ministerial staff confirmed in June 2026 that the issue is under departmental review. For context on the broader regulatory environment, see the CannIntel topic hub on Australia medicinal cannabis driving laws.

The political timeline hinges on cross-party support and alignment with national transport policy.

The ACT operates under a unicameral legislature with 25 members. Labor and the Greens hold a governing coalition, with the Greens historically supportive of cannabis reform. Any amendment to the Road Transport Act requires majority support and consultation with the National Transport Commission, which coordinates road rules across Australian states and territories.

The NTC released a discussion paper in May 2026 examining medicinal cannabis and driving, soliciting public comment through August 2026. The commission's findings will inform model legislation for state and territory adoption. ACT reform advocates expect any Canberra-specific bill to await the NTC's final recommendations to avoid regulatory divergence that could complicate interstate travel for medicinal users.

If the ACT moves unilaterally, it would become the first Australian jurisdiction to carve out a medicinal cannabis exception to drug-driving laws. That precedent could accelerate reform in Tasmania and Western Australia, where similar advocacy campaigns are active. Or the ACT may defer to a national model to preserve uniformity in roadside enforcement protocols.

The next legislative session begins in August 2026. No bill has been tabled as of July 18, 2026.